Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis

Matthias Pinter(Medical University of Vienna), Markus Peck‐Radosavljevic(Klinikum Klagenfurt), Christina Plank(BOKU University), A Maieron(Universitätsklinikum St. Pölten), Ivo Graziadei(Landeskrankenhaus Feldkirch), Adalbert Weißmann(Wilhelminen Hospital), Wolfgang Vogel(Russian State Agrarian Correspondence University), Wolfgang Sieghart(Atitus Educação), Gabriela Kornek(Medical University of Vienna), Robert Königsberg(Kaiser-Franz-Josef-Spital)
The Oncologist
January 1, 2009
10.1634/theoncologist.2008-0191
Cited by 178

Related Papers

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Meta‐analysis: <scp>ARFI</scp> elastography versus transient elastography for the evaluation of liver fibrosis
|Liver International|2013|417
Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization
|Blood|2000|322